Securities Lawsuit Adds Risk to Corcept's Relacorilant NDA

What happened

A shareholder lawsuit alleges Corcept Therapeutics failed to disclose adverse facts concerning FDA approval for relacorilant, its lead new drug for Cushing's syndrome. This legal action introduces uncertainty beyond the binary regulatory risk already priced into the stock at a ~73x P/E. Corcept's profitable Korlym franchise is stable but faces generic erosion, while the relacorilant NDA decision by year-end 2025 is the key catalyst. The lawsuit may indicate undisclosed issues that could lead to a restrictive label or complete response letter, heightening downside risk. Combined with the current valuation's slim margin of safety, this development tilts the risk-reward unfavorably.

Implication

Investors should weigh the lawsuit's potential to uncover material adverse information that could derail relacorilant's approval or limit its commercial opportunity. The already high valuation leaves little room for disappointment, and legal costs or settlements could further pressure earnings. While a clean FDA win might still lift shares, the new legal overhang makes the binary bet even less attractive. Those holding CORT should monitor lawsuit developments closely and consider reducing exposure ahead of the PDUFA date. The thesis shifts from neutral to moderately bearish pending clarity on the allegations.

Thesis delta

The shareholder lawsuit introduces legal and reputational risk that was not fully captured in the previous Hold/Neutral stance. It raises questions about management's disclosure practices and could signal hidden problems with relacorilant's regulatory path. This tilts the risk-reward toward a Sell if the allegations prove credible, as the stock's high multiple leaves no room for negative surprises.